All News
Exploring Idiopathic Myopathies
Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity. EULAR in collaboration with the American College of Rheumatology (ACR) introduced classification criteria for the major subgroups in 2017,1 but there is a need for contemporary real-world data to understand the burden – and well as new ways of assessing disease activity.
Read Article
‘Strong’ treatment predictions in inflammatory myositis
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Read Article
Vasculitis Updates: Glucocorticoid use in AAV and GCA
Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.
Read Article
Digital Platforms and AI
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
Read Article
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Bella Mehta bella_mehta ( View Tweet)
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
